Welcome to our dedicated page for QuidelOrtho Corporation news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on QuidelOrtho Corporation stock.
QuidelOrtho Corporation (symbol: QDEL) is a prominent American manufacturer specializing in diagnostic healthcare products that are distributed globally. The company focuses on the development, manufacturing, and marketing of rapid diagnostic testing solutions, which are crucial for both clinicians and patients worldwide. QuidelOrtho’s product portfolio includes immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing comprehensive solutions that aid in critical medical decisions.
With a strong geographical presence in North America, EMEA (Europe, the Middle East, and Africa), China, and other countries, QuidelOrtho generates the majority of its revenue from North America. The corporation is committed to innovation and quality, continually striving to improve diagnostic accuracy and efficiency.
Recent achievements of QuidelOrtho Corporation include significant advancements in rapid diagnostic testing technologies that ensure faster and more accurate results. The company has also entered strategic partnerships and launched new products that enhance its market position and expand its global footprint.
For investors and stakeholders, QuidelOrtho’s solid financial performance and ongoing projects demonstrate its robust growth potential. The company’s latest updates, news releases, and financial reports reflect its dedication to driving progress in the healthcare diagnostics industry.
Latest News:
- SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation announces new strategic partnerships and product launches aiming to bolster its market presence.
Quidel Corporation (NASDAQ: QDEL) has partnered with Walgreens to distribute its QuickVue® At-Home OTC COVID-19 Test at 7,600 Walgreens stores across the U.S. and Puerto Rico. This collaboration enables consumers to purchase the test over-the-counter, enhancing accessibility. Each kit includes two tests and delivers results within 10 minutes, boasting an agreement rate of 83.5% for positive results with PCR tests. The QuickVue test is authorized under FDA's Emergency Use Authorization, vital in controlling COVID-19 spread.
Quidel Corporation (NASDAQ: QDEL) announced its participation in the virtual BofA Securities 2021 Health Care Conference on May 13, 2021. CEO Douglas Bryant and CFO Randy Steward will present at 2:00 p.m. ET, detailing business and financial trends. The presentation will include previously undisclosed material information. A live webcast and audio archive will be accessible via the Investor Relations section of Quidel’s website, with replays available for 14 days. Quidel is known for its rapid diagnostic testing solutions and innovative healthcare technologies.
Quidel is hosting a free webinar on May 5 to help healthcare providers differentiate between Lyme disease, COVID-19, and the flu. With Lyme disease affecting up to 400,000 Americans annually, accurate diagnosis is crucial, especially during peak tick season. Dr. Sean McCloy will lead the session, discussing the similarities in symptoms and highlighting the Sofia® 2 Lyme FIA test, which provides results in 15 minutes. This test enhances timely treatment, allowing physicians to act quickly based on patient needs.
Quidel Corporation (NASDAQ: QDEL) will announce its fiscal Q1 2021 financial results on May 6, 2021, after market close. CEO Douglas Bryant and CFO Randy Steward will host a conference call at 5:00 PM ET to discuss the results, business developments, and address questions. The company emphasizes that the call may include material undisclosed information. A live webcast will be available on their website, with replays accessible for one year and telephone replays for 14 days starting after the call.
Quidel Corporation (NASDAQ: QDEL) has finalized a distribution agreement with McKesson Corporation to enhance access to its QuickVue® At-Home OTC COVID-19 Test. This partnership aims to expedite the rollout to various markets, including schools and businesses. McKesson will leverage its retail and e-commerce platforms to facilitate the product's distribution. The QuickVue Test, authorized by the FDA, provides results in under 10 minutes and boasts high accuracy, agreeing with PCR results 83.5% of the time. Shipping is set to commence soon.
Quidel Corporation (QDEL) announced preliminary results for Q1 2021, projecting revenues between $374 million and $376 million, marking a 114% increase from $174.7 million in Q1 2020. COVID-19 test revenues are expected to exceed $280 million, a significant rise from $1 million last year. Despite strong performance in SARS tests, influenza product sales dropped to $5 million from $79.6 million due to an uncharacteristically low respiratory season. Gross margins are estimated at 80%, with earnings growth exceeding 300%. Further details are anticipated in their earnings call on May 6, 2021.
Quidel Corporation has partnered with the Bay Area Lyme Foundation to raise public awareness about Lyme disease, which affects up to 400,000 Americans annually. The collaboration includes sponsoring a series of free speaker forums focused on Lyme disease research and prevention. The first forum will take place on May 19, addressing herbal treatments for tick-borne diseases. Additionally, Quidel will support BAL’s Emerging Leader Awards and the annual LymeAid Gala, aimed at promoting research innovation. Quidel's Sofia® 2 Lyme FIA test provides rapid, accurate results, significantly improving early diagnosis.
As Lyme disease season approaches, Quidel Corporation emphasizes the importance of awareness and testing. Up to 400,000 Americans are infected annually, with symptoms often mimicking COVID-19. Dr. Judi Tilghman advises outdoor enthusiasts to take precautionary measures against ticks and seek immediate testing if symptoms arise.
Quidel’s Sofia® 2 Lyme test offers rapid results, aiding timely diagnosis and treatment. The company's mission focuses on providing accessible, accurate health diagnostics, enhancing patient care across diverse health conditions.
Quidel Corporation (NASDAQ: QDEL) has received Emergency Use Authorization (EUA) from the FDA for its Sofia® SARS Antigen FIA. This test detects SARS-CoV-2 antigens from nasal swabs, allowing usage without a prescription for asymptomatic individuals under specific testing conditions. The test shows a strong correlation with PCR results (96.7% agreement for positives, 100% for negatives) within five days of symptom onset. While the company aims for broad application to enhance early detection, ongoing studies seek to confirm clinical performance among asymptomatic patients.
Quidel Corporation (NASDAQ: QDEL) has been named the Official Diagnostics Partner of the San Diego Padres, a Major League Baseball franchise. Quidel will supply its Sofia® 2 instruments and Sofia® SARS Antigen tests to support the Padres' medical staff and event personnel, enhancing safety measures at Petco Park. This partnership aims to ensure a safe experience for attendees during games, with rapid test results delivered in just 15 minutes. Quidel has been at the forefront of COVID-19 testing innovation, underscoring its commitment to public health in the San Diego community.
FAQ
What is the current stock price of QuidelOrtho Corporation (QDEL)?
What is the market cap of QuidelOrtho Corporation (QDEL)?
What does QuidelOrtho Corporation specialize in?
Where is QuidelOrtho Corporation headquartered?
What are the main products offered by QuidelOrtho?
How does QuidelOrtho support clinicians and patients?
What recent achievements has QuidelOrtho Corporation made?
What regions contribute most to QuidelOrtho's revenue?
What is the stock symbol for QuidelOrtho Corporation?
How can I stay updated with the latest news about QuidelOrtho?
Does QuidelOrtho engage in any partnerships?
What is the primary focus of QuidelOrtho's diagnostics?
